JP2005506326A - 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体 - Google Patents

抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体 Download PDF

Info

Publication number
JP2005506326A
JP2005506326A JP2003526419A JP2003526419A JP2005506326A JP 2005506326 A JP2005506326 A JP 2005506326A JP 2003526419 A JP2003526419 A JP 2003526419A JP 2003526419 A JP2003526419 A JP 2003526419A JP 2005506326 A JP2005506326 A JP 2005506326A
Authority
JP
Japan
Prior art keywords
heparin
desulfated
partially
acetyl
uronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003526419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506326A5 (cg-RX-API-DMAC7.html
Inventor
ベニト・カス
ジャンジャコモ・トッリ
アンナマリア・ナッジ
ジュゼッペ・ジャンニーニ
クラウディオ・ピサノ
セルジョ・ペンコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2005506326A publication Critical patent/JP2005506326A/ja
Publication of JP2005506326A5 publication Critical patent/JP2005506326A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
JP2003526419A 2001-09-12 2001-09-12 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体 Pending JP2005506326A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2001/000472 WO2003022291A1 (en) 2001-09-12 2001-09-12 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013112054A Division JP6132302B2 (ja) 2013-05-28 2013-05-28 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体

Publications (2)

Publication Number Publication Date
JP2005506326A true JP2005506326A (ja) 2005-03-03
JP2005506326A5 JP2005506326A5 (cg-RX-API-DMAC7.html) 2008-11-27

Family

ID=11133723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003526419A Pending JP2005506326A (ja) 2001-09-12 2001-09-12 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体

Country Status (19)

Country Link
US (1) US20050137167A1 (cg-RX-API-DMAC7.html)
EP (2) EP1427427B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506326A (cg-RX-API-DMAC7.html)
KR (1) KR100855331B1 (cg-RX-API-DMAC7.html)
CN (1) CN1547477B (cg-RX-API-DMAC7.html)
AT (1) ATE511846T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001292231B2 (cg-RX-API-DMAC7.html)
BR (1) BR0117124A (cg-RX-API-DMAC7.html)
CA (1) CA2457719C (cg-RX-API-DMAC7.html)
CY (2) CY1112551T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ307433B6 (cg-RX-API-DMAC7.html)
DK (1) DK1427427T3 (cg-RX-API-DMAC7.html)
ES (2) ES2431362T3 (cg-RX-API-DMAC7.html)
HU (1) HU230385B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04002217A (cg-RX-API-DMAC7.html)
PT (2) PT2343077E (cg-RX-API-DMAC7.html)
SI (1) SI1427427T1 (cg-RX-API-DMAC7.html)
SK (1) SK288335B6 (cg-RX-API-DMAC7.html)
WO (1) WO2003022291A1 (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501838A (ja) * 2009-08-14 2013-01-17 サノフイ Ｆｇｆ受容体活性化ｎ−硫酸塩オリゴ糖、該オリゴ糖の調製および該オリゴ糖の治療用途
JP2013522172A (ja) * 2010-03-12 2013-06-13 ジ オーストラリアン ナショナル ユニバーシティ ヘパラン硫酸補充療法
JP2014503674A (ja) * 2011-01-27 2014-02-13 サノフイ Ｆｇｆ受容体活性化３−ｏ−アルキルオリゴ糖類、これの調製およびこれの治療的使用
JP2016520697A (ja) * 2013-05-16 2016-07-14 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ヘパラン硫酸
JP2017507210A (ja) * 2013-10-31 2017-03-16 ノバヘルス バイオシステムズ エルエルシーＮｏｖａｈｅａｌｔｈ Ｂｉｏｓｙｓｔｅｍｓ Ｌｌｃ Ｎ−脱硫酸化グルコサミノグリカンの誘導体、及び薬物としての使用
JP2017508836A (ja) * 2013-11-06 2017-03-30 ノバヘルス バイオシステムズ エルエルシーＮｏｖａｈｅａｌｔｈ Ｂｉｏｓｙｓｔｅｍｓ Ｌｌｃ グルコサミノグリカンのカルボキシル化誘導体、及び薬物としての使用
JP2020515633A (ja) * 2017-03-23 2020-05-28 ヴィクトリア リンク リミテッド ヘパラン硫酸糖模倣物化合物並びにその医薬品及び薬用化粧品としての使用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1819833A (zh) * 2004-03-29 2006-08-16 克霖固鲁制药股份有限公司 促进hgf产生的含肝素类寡糖的药剂
JP5404406B2 (ja) * 2006-10-20 2014-01-29 ジ オーストラリアン ナショナル ユニバーシティ 細胞外マトリクスの分解の阻害
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
FI20085308A0 (fi) * 2008-04-11 2008-04-11 Polysackaridforskning I Uppsal Heparanaasittomia ihmiskuntaan kuulumattomia nisäkkäitä
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
JP5905455B2 (ja) 2010-06-17 2016-04-20 モメンタ ファーマシューティカルズ インコーポレイテッド 発毛を促進する方法および組成物
KR101522604B1 (ko) * 2013-03-21 2015-05-26 대한민국 곤충 글라이코자미노글라이칸 유래 헤파린 단편 및 이의 제조 방법
CA2910837A1 (en) 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
ES2715556T3 (es) 2015-03-06 2019-06-04 Leadiant Biosciences Sa In Liquidazione Terapia combinada con roneparstat del mieloma múltiple
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
BR112019012045A2 (pt) 2016-12-13 2020-08-18 Beta Therapeutics Pty Ltd inibidores de heparanase e uso dos mesmos
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
EP3388439A1 (en) 2017-04-11 2018-10-17 Leadiant Biosciences SA Biotin-conjugated n-acetyl glycol split heparin
US11225531B2 (en) * 2018-02-02 2022-01-18 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Glycosaminoglycan derivative and preparation method therefor and use thereof
EP3705126A1 (en) 2019-03-05 2020-09-09 Leadiant Biosciences S.p.A. Roneparstat for the treatment of amyloidosis
WO2021128253A1 (zh) * 2019-12-27 2021-07-01 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用
CA3187652A1 (en) * 2020-07-02 2022-01-06 Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer) Marine bacterial exopolysaccharide derivatives and uses thereof in the treatment of mucopolysaccharidoses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265998A (ja) * 1986-03-10 1987-11-18 ボ−ド　オブ　リ−ジエンツ　ザ　ユニヴア−シテイ　オブ　テキサス　システム ヘパラン硫酸エンドグリコシダーゼアッセイ
JPS6388128A (ja) * 1986-06-26 1988-04-19 イエダ　リサ−チ　アンド　デベロツプメント　カンパニ−　リミテツド 腫瘍細胞転移抑制剤
JPS63278901A (ja) * 1987-04-16 1988-11-16 サノフィ 通常の構造の低分子量のヘパリンとその製法並びに生物学的な応用
JPH10218902A (ja) * 1997-01-31 1998-08-18 Seikagaku Kogyo Co Ltd 低分子化硫酸化多糖、その製造法及び医薬組成物
WO2001055521A1 (en) * 1998-09-22 2001-08-02 Nippon Eisei Center Co., Ltd. Earthquake-proofing reinforcing metal fitting
JP2001527583A (ja) * 1994-09-01 2001-12-25 グリコメド・インコーポレイテッド ヘパリンのｏ−脱硫酸化の制御方法およびそれによって得られる組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
IE61758B1 (en) 1986-05-23 1994-11-30 Daiichi Seiyaku Co Use of a sulfated polysaccharide
IL79254A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Compositions for preventing graft rejection
AU7852687A (en) * 1986-08-21 1988-03-08 University Of Texas System, The Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
IL85145A (en) 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
CZ195193A3 (en) 1992-09-25 1994-04-13 Lilly Co Eli Modified factor-4 of blood platelets, process of its preparation and pharmaceutical preparation in which it is comprised
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5399667A (en) 1993-03-05 1995-03-21 Washington University Thrombospondin receptor binding peptides
IT1264101B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2
IT1264709B1 (it) * 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
AU7520394A (en) 1993-08-13 1995-03-14 Glycomed Incorporated Bridged oligosaccharides and sulfated derivatives thereof
JPH09503510A (ja) 1993-10-07 1997-04-08 グリコメド・インコーポレイテッド ヘパリン様特性を有する高硫酸化マルトオリゴ糖
US5739115A (en) 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
AU2435795A (en) 1994-05-06 1995-11-29 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
AUPN261895A0 (en) 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
DE19955803A1 (de) 1999-11-19 2001-05-23 Knoll Ag Verwendung von Heparanase-Inhibitoren zur Behandlung von Hersinsuffizienz
IT1316986B1 (it) * 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265998A (ja) * 1986-03-10 1987-11-18 ボ−ド　オブ　リ−ジエンツ　ザ　ユニヴア−シテイ　オブ　テキサス　システム ヘパラン硫酸エンドグリコシダーゼアッセイ
JPS6388128A (ja) * 1986-06-26 1988-04-19 イエダ　リサ−チ　アンド　デベロツプメント　カンパニ−　リミテツド 腫瘍細胞転移抑制剤
JPS63278901A (ja) * 1987-04-16 1988-11-16 サノフィ 通常の構造の低分子量のヘパリンとその製法並びに生物学的な応用
JP2001527583A (ja) * 1994-09-01 2001-12-25 グリコメド・インコーポレイテッド ヘパリンのｏ−脱硫酸化の制御方法およびそれによって得られる組成物
JPH10218902A (ja) * 1997-01-31 1998-08-18 Seikagaku Kogyo Co Ltd 低分子化硫酸化多糖、その製造法及び医薬組成物
WO2001055521A1 (en) * 1998-09-22 2001-08-02 Nippon Eisei Center Co., Ltd. Earthquake-proofing reinforcing metal fitting

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501838A (ja) * 2009-08-14 2013-01-17 サノフイ Ｆｇｆ受容体活性化ｎ−硫酸塩オリゴ糖、該オリゴ糖の調製および該オリゴ糖の治療用途
JP2013522172A (ja) * 2010-03-12 2013-06-13 ジ オーストラリアン ナショナル ユニバーシティ ヘパラン硫酸補充療法
JP2014503674A (ja) * 2011-01-27 2014-02-13 サノフイ Ｆｇｆ受容体活性化３−ｏ−アルキルオリゴ糖類、これの調製およびこれの治療的使用
JP2016520697A (ja) * 2013-05-16 2016-07-14 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ヘパラン硫酸
US11248063B2 (en) 2013-10-31 2022-02-15 Novahealth Biosystems, Llc Derivatives of N-desulfated glycosaminoglycans and use as drugs
US10875936B2 (en) 2013-10-31 2020-12-29 Novahealth Biosystems, Llc Derivatives of N-desulfated glycosaminoglycans and use as drugs
JP2017507210A (ja) * 2013-10-31 2017-03-16 ノバヘルス バイオシステムズ エルエルシーＮｏｖａｈｅａｌｔｈ Ｂｉｏｓｙｓｔｅｍｓ Ｌｌｃ Ｎ−脱硫酸化グルコサミノグリカンの誘導体、及び薬物としての使用
JP2017508836A (ja) * 2013-11-06 2017-03-30 ノバヘルス バイオシステムズ エルエルシーＮｏｖａｈｅａｌｔｈ Ｂｉｏｓｙｓｔｅｍｓ Ｌｌｃ グルコサミノグリカンのカルボキシル化誘導体、及び薬物としての使用
US10822430B2 (en) 2013-11-06 2020-11-03 Novahealth Biosystems, Llc Carboxylated derivatives of glycosaminoglycans and use as drugs
US11332548B2 (en) 2013-11-06 2022-05-17 Novahealth Biosystems, Llc Carboxylated derivatives of glycosaminoglycans and use as drugs
US11370848B2 (en) 2013-11-06 2022-06-28 Novahealth Biosystems, Llc Carboxylated derivatives of glycosaminoglycans and use as drugs
JP2020515633A (ja) * 2017-03-23 2020-05-28 ヴィクトリア リンク リミテッド ヘパラン硫酸糖模倣物化合物並びにその医薬品及び薬用化粧品としての使用
JP7121110B2 (ja) 2017-03-23 2022-08-17 ヴィクトリア リンク リミテッド ヘパラン硫酸糖模倣物化合物並びにその医薬品及び薬用化粧品としての使用

Also Published As

Publication number Publication date
SK1602004A3 (en) 2004-08-03
WO2003022291A1 (en) 2003-03-20
PT2343077E (pt) 2013-08-29
EP2343077B1 (en) 2013-07-17
HUP0401693A2 (hu) 2004-12-28
ES2431362T3 (es) 2013-11-26
CZ2004255A3 (cs) 2004-11-10
HK1069537A1 (en) 2005-05-27
AU2001292231B2 (en) 2008-06-05
BR0117124A (pt) 2004-09-28
DK1427427T3 (da) 2011-09-19
CY1112551T1 (el) 2016-02-10
CN1547477A (zh) 2004-11-17
KR20040048404A (ko) 2004-06-09
SI1427427T1 (sl) 2011-10-28
PT1427427E (pt) 2011-09-13
HU230385B1 (hu) 2016-03-29
SK288335B6 (sk) 2016-02-02
EP2343077A1 (en) 2011-07-13
CY1114544T1 (el) 2016-10-05
KR100855331B1 (ko) 2008-09-04
ATE511846T1 (de) 2011-06-15
EP1427427A1 (en) 2004-06-16
CZ307433B6 (cs) 2018-08-22
ES2367778T3 (es) 2011-11-08
CA2457719A1 (en) 2003-03-20
CN1547477B (zh) 2010-12-22
MXPA04002217A (es) 2004-07-08
US20050137167A1 (en) 2005-06-23
CA2457719C (en) 2012-01-03
EP1427427B1 (en) 2011-06-08
HUP0401693A3 (en) 2009-06-29

Similar Documents

Publication Publication Date Title
JP2005506326A (ja) 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
US8067555B2 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
AU2001292231A1 (en) Derivatives of partially desulphated glycogaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
JP4514240B2 (ja) 硫酸化オリゴ糖の製造および使用
JP6132302B2 (ja) 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
JPH11504018A5 (cg-RX-API-DMAC7.html)
EP2025687A1 (en) Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
EP1551852A2 (en) Methods and products for mucosal delivery
JPH0273801A (ja) 選択的にｏ―アシル化されたグリコサミノグリカン
JP4412756B2 (ja) 新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物
JP2016014148A (ja) 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
AU2008202261B2 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US20080139503A1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
HK1069537B (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
PL212357B1 (pl) Zmodyfikowana heparyna, jej zastosowanie i zawierająca ją kompozycja farmaceutyczna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080911

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120229

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120